Artificial intelligence could improve therapy for lymphoma
Hodgkin’s lymphoma, a type of lymph node cancer, requires chemotherapy and radiation therapy that can be very stressful for patients. A research group in Vienna is working on a method to predict the course of the disease with the help of artificial intelligence algorithms. This would facilitate a fine-tuning of treatment methods.
It is particularly young people that are affected by Hodgkin’s lymphoma. While this form of cancer, which develops in the lymph glands, is particularly aggressive and can spread quickly, it comes with good chances of a cure. Treatment, however, is often accompanied by serious short-term and long-term side effects. The standard treatment is chemotherapy, but patients affected by certain subtypes of this lymphoma also need to undergo radiation therapy.
Researchers at the Nuclear Medicine Division of the Medical University of Vienna at the Vienna General Hospital (AKH) are now looking for new ways to improve diagnostics. Co-funded by the Austrian Science Fund FWF, the three-year project HOLY-2020: Individualized Therapy in Hodgkin Lymphoma has them working with European partners on a new method that combines imaging medicine with artificial intelligence.
“The diagnostic methods currently used to predict the course of the disease are relatively crude and inaccurate. We are using artificial intelligence algorithms to improve the accuracy of predictions,” explains Alexander Haug, deputy head of the Clinical Department of Nuclear Medicine. One of the benefits of the new diagnostic tool could be to provide clarity earlier on about whether aggressive radiotherapy is required or whether chemotherapy is sufficient, thereby increasing the certainty that patients receive adequate treatment.
Nuclear medicine visualizes tumors
The current gold standard of diagnostics for Hodgkin’s lymphoma can map the cancer cells in the body with high accuracy. This approach uses a combination of positron emission tomography (PET) and computed tomography (CT). Patients are administered very weakly radioactively labelled glucose which is absorbed by the body’s cells. Tumor cells have higher energy requirements and quickly absorb a lot more of these labelled sugar molecules than normal body cells.
PET scans show a precise distribution of radioactive sugar molecules, thereby mapping the size and shape of the lymphoma. By combining them with CT images, which provide a 3D image of the inside of the body, one can pinpoint the position of the cancer cells in the body and thus determine very precisely how far the cancer has progressed in the body. The degree to which individual regions are affected provides indications on risk factors and chances of cure.
Haug and his team assume that the PET and CT images contain even more information than is gleaned by existing evaluations. For instance, the data show the distribution of intensities within the lymphomas. At some sites, a much higher numbers of sugar molecules are measured than at others. The researchers’ analyses have revealed dozens of different parameters that can be distinguished on the basis of this heterogeneous distribution. “Even the trained eye cannot draw any conclusions about disease progression from these patterns,” says Haug. “But we are confident that artificial intelligence will be able to use it to predict prognosis.”
Training based on existing patient data
In order to develop an appropriate AI system, the team analyzes the PET/CT images and links them to the course of the disease in the respective patients. This is then fed to the self-learning algorithms as training data. The AI thus learns which of the patterns that lie hidden in the images are associated with good or bad prognoses. When confronted with new image data that was not part of the training, the AI tool should eventually be able to provide new prognostic assessments. In medical science, this type of interpretation of image features in radiology is also known as radiomics.
In this project, Haug and his colleagues at the Medical University of Vienna are collaborating with research institutes in Paris and Barcelona. Overall, the researchers have already collected more than 200 data sets on different disease courses in Hodgkin’s lymphoma. Initial AI analyses are now underway. “Data harmonization is a particular challenge with many radiomics solutions,” notes Haug. “Images from different scanners differ in details. Color shading, for instance, is always slightly different from one scanner to the next. First we must standardize such properties in a time-consuming process.”
Set to run until fall 2023, the project aims to confirm that this kind of AI diagnostics is essentially possible. In subsequent research, the approach could then be further developed with a view to practical application.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Category:Psilocybe
A fungus converts cellulose directly into a novel platform chemical - A new process for the mass production of erythro-isocitric acid from waste could make the substance interesting for industry in the future
Bruker Announces Acquisition of Inscopix for Neuroscience Research - Head-Mounted Miniscopes Expand Neural Functional Imaging Capabilities
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration - Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Hopes of a New Treatment Approach for Paralysis
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform - AstriVax to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection
Manufacturers in the laboratory sector choose analytica - Large number of exhibitors registered more than a year before analytica
Eurofins agrees to acquire SYNLAB’s clinical diagnostics operations in Spain
Hepatocellular_carcinoma
Paget's_disease_of_the_breast
